Priya Singhal
Head of DevelopmentBiogen
ProductView Profile →Executive Vice President and Chief Product Affairs Officer · Vertex Pharmaceuticals
Nia Tatsis oversees product affairs, global regulatory affairs and quality at Vertex Pharmaceuticals. Her career spans immunology research and regulatory leadership at biotechnology and pharmaceutical companies.
Last reviewed: Nov 2, 2026
Executive Vice President and Chief Product Affairs Officer
Vertex Pharmaceuticals
Last Reviewed: November 2, 2026
Nia Tatsis oversees product affairs, global regulatory affairs and quality at Vertex Pharmaceuticals. Her career spans immunology research and regulatory leadership at biotechnology and pharmaceutical companies.
Tatsis developed her scientific background through a postdoctoral immunology fellowship at Thomas Jefferson University and work as a staff scientist and research fellow at the Wistar Institute, where her research involved immunology and vaccine development.
She subsequently worked at Wyeth, Pfizer and Stemnion before holding senior regulatory responsibilities at Sanofi. From 2014 to 2017, she was vice president and head of global regulatory affairs at Sanofi Genzyme. Her remit covered multiple therapeutic areas, including rare diseases, multiple sclerosis, inflammation and immunology, neurology and oncology.
Tatsis joined Vertex in September 2017 as senior vice president of global regulatory affairs. She became senior vice president and chief regulatory officer in October 2019, then executive vice president and chief regulatory and quality officer in August 2020. These positions placed her across the regulatory requirements of clinical development, manufacturing and commercialization.
As chief product affairs officer, she now oversees key programs across the product life cycle while continuing to lead regulatory affairs and quality. Her work connects research, clinical development and commercial teams.
Outside Vertex, Tatsis serves on Odyssey Therapeutics’ board and the International Institute of New England’s Leadership Council. She previously served on the boards of Verve Therapeutics and the institute. Her industry recognition includes the PharmaVoice 100 and Endpoints News Women Leading Biopharma R&D lists in 2024.
Tatsis holds a Bachelor of Science in biology from Temple University and a PhD in cell and molecular biology from the University of Vermont. She completed a postdoctoral research fellowship in immunology at Thomas Jefferson University.